4-(甲基磺酰基)苯-1,2-二胺 | 21731-57-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(甲基磺酰基)苯-1,2-二胺
• 中文别名: 3,4-二氨基苯甲砜
• 英文名称: 4-methanesulfonylbenzene-1,2-diamine
• 英文别名: 4-(methylsulfonyl)benzene-1,2-diamine；4-Methylsulfonyl-1,2-diaminobenzol；5-methylsulphonyl-1,2-phenylenediamine；4-methylsulfonylbenzene-1,2-diamine
• CAS: 21731-57-7
• 化学式: C₇H₁₀N₂O₂S
• mdl: MFCD00720917
• 分子量: 186.235
• InChiKey: XWUNCRCMUXPZDR-UHFFFAOYSA-N

物化性质

• 熔点：
  156-158 °C
• 沸点：
  457.3±45.0 °C(Predicted)
• 密度：
  1.371±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  94.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2921590090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Methanesulfonylbenzene-1,2-diamine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Methanesulfonylbenzene-1,2-diamine
CAS number: 21731-57-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H10N2O2S
Molecular weight: 186.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(甲基磺酰基)苯-1,2-二胺 在 氢氧化钾 、 氯化亚砜 、 乙醇 、 sodium methylate 、 间氯过氧苯甲酸 作用下， 以 氯仿 、 水 为溶剂， 反应 15.0h， 生成 5-Methanesulfonyl-2-[3-methyl-4-(2,2,2-trifluoro-ethoxy)-pyridin-2-ylmethanesulfinyl]-1H-benzoimidazole
  参考文献：
  名称：

  Synthesis of 2-(((4-fluoroalkoxy-2-pyridyl)methyl)sulfinyl)-1H-benzimidazoles as antiulcer agents.

  摘要：

  合成了许多2-[[（4-氟烷氧基-2-吡啶基）甲基]亚磺酰基]-1H-苯并咪唑，并测试了其抗分泌、抗溃疡和细胞保护活性。这些化合物在抗分泌和抗溃疡效能方面大多优于奥美拉唑，尤其是在保护胃黏膜免受乙醇诱导损伤方面。在这些化合物中，2-[[[3-甲基-4-(2,2,2-三氟乙氧基)-2-吡啶基]甲基]亚磺酰基]-1H-苯并咪唑，AG-1749（兰索拉唑）（6f）被选中进行进一步开发和临床评估。

  DOI：

  10.1248/cpb.38.2853
• 作为产物：
  描述：

  2-amino-4-methylthio-1-nitrobenzene 在 palladium 10% on activated carbon 、 氢气 、 间氯过氧苯甲酸 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 2.33h， 生成 4-(甲基磺酰基)苯-1,2-二胺
  参考文献：
  名称：

  苯并咪唑类衍生物、其制备方法及其在医药学上的应用

  摘要：

  本发明涉及一种新的调控或抑制吲哚胺2,3‑双加氧酶（IDO）活性的苯并咪唑类衍生物，其制备方法及其在医药学上的应用。具体而言，本发明涉及一种通式（I）所示的化合物及其可药用的盐、含有所述化合物或其可药用的盐的药物组合物、应用所述化合物或其可药用的盐治疗和/或预防IDO介导的相关性病症、特别是肿瘤的方法以及所述化合物或其可药用的盐的制备方法。本发明还涉及所述化合物或其可药用的盐或含有所述化合物或其可药用的盐的药物组合物在制备用于治疗和/或预防IDO介导的相关性病症、特别是肿瘤的药物中的用途。其中通式（I）的各取代基与说明书中的定义相同。

  公开号：

  CN109956927A

文献信息

• 5(6)-Benzene ring substituted benzimidazole-2-carbamate derivatives
  申请人：Syntex (U.S.A.) Inc.

  公开号：US04072696A1

  公开（公告）日：1978-02-07

  Carbalkoxythioureidobenzene derivatives represented by the following formula: ##STR1## where R is a lower alkyl group having 1 to 4 carbon atoms; R.sup.1 is --SR.sup.2, --SOR.sup.2, --SO.sub.2 R.sup.2, --OR.sup.2, --SCN, --SC(O)NR.sup.3 R.sup.4, or --M'(CH.sub.2).sub.n MR.sup.7 where n is 1-4; R.sup.2 is lower alkyl having 1 to 6 carbon atoms, cycloalkyl having 3 to 7 carbon atoms, lower alkenyl or lower alkynyl having 3 to 6 carbon atoms, aralkyl or aryl, provided that when R.sup.1 is --SO.sub.2 R.sup.2, R.sup.2 is not aralkyl or phenyl; R.sup.3 and R.sup.4 are independently hydrogen or lower alkyl having 1 to 6 carbon atoms; Y is amino, nitro, acylamino where the acyl portion has 1 to 6 carbon atoms, --NHC(O) (CH.sub.2).sub.m COOH where m is 1-6, or --NHC(S)NHCOOR; M and M' are independently O, S or ##STR2## and R.sup.7 is lower alkyl having 1 to 4 carbon atoms or aryl. The R.sup.1 substitution is either at the 4- or 5-position. The compounds are useful as pesticides, particularly as anthelmintic and antifungal agents.

  以下是该公式代表的Carbalkoxythioureidobenzene衍生物的中文翻译：其中R是具有1至4个碳原子的低碳基团；R.sup.1是--SR.sup.2，--SOR.sup.2，--SO.sub.2 R.sup.2，--OR.sup.2，--SCN，--SC(O)NR.sup.3 R.sup.4，或--M'(CH.sub.2).sub.n MR.sup.7，其中n为1-4；R.sup.2是具有1至6个碳原子的低碳基，具有3至7个碳原子的环烷基，具有3至6个碳原子的低烯基或低炔基，芳基烷基或芳基，但当R.sup.1为--SO.sub.2 R.sup.2时，R.sup.2不是芳基烷基或苯基；R.sup.3和R.sup.4独立地是氢或具有1至6个碳原子的低碳基；Y是氨基，硝基，酰胺基，其中酰基部分具有1至6个碳原子，--NHC(O) (CH.sub.2).sub.m COOH，其中m为1-6，或--NHC(S)NHCOOR；M和M'独立地是O，S或##STR2##，R.sup.7是具有1至4个碳原子的低碳基或芳基。R.sup.1取代物位于4-或5-位置。这些化合物可用作杀虫剂，特别是作为驱虫剂和抗真菌剂。
• [EN] BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS<br/>[FR] DÉRIVÉS HÉTÉROARYLE BICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE L'ECTONUCLÉOTIDE PYROPHOSPHATASE/PHOSPHODIESTÉRASE 1
  申请人：RIBOSCIENCE LLC

  公开号：WO2020210649A1

  公开（公告）日：2020-10-15

  The present disclosure provides certain bicyclic heteroaryl compounds that inhibit ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzymatic activity and are therefore useful for the treatment of diseases and conditions modulated at least in part by ENPP1. In some embodiments, the bicyclic heteroaryl compounds includes those of Formula (I). Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本公开提供了一些抑制细胞外核苷酸焦磷酸酶/磷酸二酯酶1（ENPP1）酶活性的双环杂环芳基化合物，因此对于治疗至少部分受ENPP1调节的疾病和病况是有用的。在某些实施例中，双环杂环芳基化合物包括式（I）中的化合物。本文还提供了含有这类化合物的药物组合物以及制备这类化合物的方法。
• [EN] INHIBITORS OF CD40-CD154 BINDING<br/>[FR] INHIBITEURS DE LIAISON CD40-CD154
  申请人：TONIX PHARMACEUTICALS HOLDING CORP

  公开号：WO2020210831A1

  公开（公告）日：2020-10-15

  Disclosed herein are compounds including pharmaceutically acceptable salts, esters, prodrugs, hydrates and tautomers thereof which modulate the interactions of CD-40-CD40L. The compounds are useful for treating, ameliorating or preventing an autoimmune disease, inflammatory disease, or other immune-related disease in a patient in need of treatment.

  本文披露了包括药用可接受的盐、酯、前药、水合物和互变异构体在内的化合物，这些化合物调节CD-40-CD40L的相互作用。这些化合物可用于治疗、改善或预防患有自身免疫疾病、炎症性疾病或其他免疫相关疾病的患者。
• [EN] TYROSINE KINASE INHIBITORS, COMPOSITIONS AND METHODS THERE OF<br/>[FR] INHIBITEURS DE TYROSINE KINASE, COMPOSITIONS ET PROCÉDÉS ASSOCIÉS
  申请人：BETTA PHARMACEUTICALS CO LTD

  公开号：WO2020114499A1

  公开（公告）日：2020-06-11

  The present invention relates to compounds of Formula (I), methods of using the compounds as Trk inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections. (I)

  本发明涉及式(I)的化合物，使用这些化合物作为Trk抑制剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或改善癌症或感染等疾病或疾病方面是有用的。 (I)
• Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
  申请人：——

  公开号：US20040266668A1

  公开（公告）日：2004-12-30

  The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: 1 which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及式I或II的化合物，或其药学上可接受的盐、酯或前药：1，其抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰乙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及含有上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给受试者投予含有本发明化合物的药物组合物来治疗HCV感染的方法。